By Hilary Rosselot
Zynerba Pharmaceuticals Presents During the 2022 Industry Updates Keynote at the 18th International Fragile X Conference
Stephen O’Quinn, Vice President Medical Affairs at Zynerba Pharmaceuticals, presented about ZYN002, a clear, non-plant derived, cannabidiol gel, during the Industry Updates keynote session at the 18th International Fragile X Conference. ZYN002 is in Phase 3 trials in Fragile X Syndrome with the goal of becoming an FDA-approved treatment for the behavioral symptoms of FXS. Zynerba is now enrolling participants in their RECONNECT trial. More information about the RECONNECT trial can be found here.
Stephen spoke about the status Zynerba’s Fragile X program, including the results of their CONNECT-FX trial and their current RECONNECT trial, where they hope to go, and the value of partnering with families with Fragile X. Learn more about Zynerba and ZYN002 by watching their 2022 Industry Updates presentation or vising their MyFXResearch post.
about
Hilary Rosselot
Hilary joined the NFXF team in 2019. Prior to joining the NFXF team, she worked at the Cincinnati Fragile X Research and Treatment Center for over five years. She has experience as a clinical research coordinator across many types of clinical trials and served as the clinical research manager for the Cincinnati program. She earned a bachelor’s degree in psychology, a master’s, and is a SOCRA certified clinical research professional (CCRP). She enjoys time with family and friends, a great book, a strong cup of coffee and, of course, a good laugh!
learn more
Grief and Bereavement Experiences of Children with Intellectual Disabilities
Researchers at the University of Maryland are looking to understand how children with Fragile X syndrome (FXS) and other intellectual disabilities grieve the loss of a loved one. If you are the parent or guardian of a child with FXS or another intellectual disability who has experienced the death of someone in their life when they were 5-17 years old, researchers want to talk to you.
Language Learning in Children: Vocabulary Acquisition in a Meaningful Context
The University of Washington's Neurodevelopmental Language and Learning (NeuDLL) Lab is conducting research addressing how children learn words in stories and the skills that support learning. Participation is remote and can be completed from home. Sessions are scheduled at your convenience.